Tribet 2
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching the Web
Tribet 2 tablet glimepiride metformin voglibose composition uses dose
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
I now have all the information needed for a thorough answer. Here is the complete profile of Tribet 2:
Tribet 2 - Complete Drug Profile
Composition
Tribet 2 is a fixed-dose combination (FDC) bilayered tablet containing:
| Component | Strength in Tribet 2 |
|---|---|
| Glimepiride IP | 2 mg |
| Metformin Hydrochloride SR (sustained-release) | 500 mg |
| Voglibose IP | 0.2 mg |
(Tribet 1 contains glimepiride 1 mg; Tribet 2 contains glimepiride 2 mg - both have the same metformin and voglibose doses.)
Therapeutic Class
Triple oral antidiabetic combination - used in Type 2 Diabetes Mellitus (T2DM). The combination targets three separate pathophysiological mechanisms simultaneously:
- Impaired insulin secretion (glimepiride)
- Hepatic overproduction of glucose (metformin)
- Postprandial glucose spike from carbohydrate digestion (voglibose)
Indication
Third-line treatment of Type 2 DM in adults when diet, exercise, and single-agent or dual-agent therapy (e.g., metformin alone, or glimepiride + metformin) have not achieved adequate glycemic control.
Individual Components - Mechanisms & Pharmacology
1. Glimepiride (2 mg) - Sulfonylurea
Mechanism: Glimepiride is a second-generation sulfonylurea and insulin secretagogue. It blocks ATP-sensitive K⁺ channels on pancreatic β-cells, leading to membrane depolarization, calcium influx, and exocytosis of insulin. - Lippincott Illustrated Reviews Pharmacology, p. 813
Key pharmacokinetics:
- Taken once daily - achieves blood glucose lowering at the lowest dose of any sulfonylurea
- A single 1 mg dose is effective; the recommended maximum daily dose is 8 mg
- Half-life under multidose conditions: 5-9 hours
- Completely metabolized by the liver to metabolites with weak or no activity
- Safer than glyburide in renal dysfunction and in elderly patients
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
2. Metformin SR 500 mg - Biguanide
Mechanism: The main mechanism is reduction of hepatic gluconeogenesis (targets the major source of fasting hyperglycemia). It also slows intestinal absorption of sugars and improves peripheral glucose uptake and insulin sensitivity. Critically, it does NOT stimulate insulin secretion, so it carries low intrinsic hypoglycemia risk. - Lippincott Illustrated Reviews Pharmacology, p. 812
Key pharmacokinetics:
- SR (sustained-release) formulation reduces GI side effects and allows once-daily dosing
- Not bound to serum proteins, not metabolized - excreted unchanged by the kidneys
- Contraindicated if eGFR < 30 mL/min/1.73 m² (risk of lactic acidosis)
- Should be temporarily held before IV contrast procedures
3. Voglibose (0.2 mg) - Alpha-glucosidase Inhibitor
Mechanism: Voglibose (like acarbose and miglitol) reversibly inhibits α-glucosidase enzymes located in the intestinal brush border. These enzymes normally break down complex carbohydrates into absorbable simple sugars. When taken at the start of a meal, voglibose delays carbohydrate digestion and absorption, blunting the postprandial glucose spike. - Lippincott Illustrated Reviews Pharmacology, p. 820
Key properties:
- Does NOT stimulate insulin release or increase insulin sensitivity
- Does NOT cause hypoglycemia as monotherapy
- If hypoglycemia occurs (due to glimepiride component), treat with glucose (dextrose), NOT sucrose, because sucrase activity is also inhibited
- Main adverse effects: flatulence, diarrhea, abdominal cramping (due to fermentation of undigested carbohydrates in the colon)
How to Take
- One tablet twice daily, taken before meals (with or just before eating)
- Dose should be individualized based on efficacy and tolerability
- Start at a low dose and titrate based on therapeutic response
- Patients inadequately controlled on dual therapy (glimepiride + metformin) may be uptitrated from Tribet 1 to Tribet 2 after assessing HbA1c (typically after 12 weeks, if HbA1c > 7.5%)
Contraindications
- Type 1 diabetes / DKA (diabetic ketoacidosis)
- Renal impairment (eGFR < 30 mL/min) - due to metformin
- Severe hepatic impairment
- Pregnancy and lactation (insulin preferred)
- Hypersensitivity to any component
- Inflammatory bowel disease or significant GI disorders (due to voglibose)
Adverse Effects Summary
| Component | Key Adverse Effects |
|---|---|
| Glimepiride | Hypoglycemia, weight gain, hyperinsulinemia |
| Metformin SR | GI upset (nausea, diarrhea - reduced with SR form), lactic acidosis (rare), Vitamin B12 deficiency |
| Voglibose | Flatulence, abdominal bloating, diarrhea (most common) |
Drug Interactions
- Potentiate hypoglycemia: NSAIDs, salicylates, sulfonamides, warfarin, fibrates, beta-blockers, MAO inhibitors (with glimepiride component)
- Reduce glycemic control: Corticosteroids, thiazide diuretics, oral contraceptives, thyroid hormones, sympathomimetics
- Metformin: Cationic drugs eliminated by renal tubular secretion (e.g., cimetidine, trimethoprim) may increase metformin accumulation; iodinated contrast may precipitate acute kidney injury and lactic acidosis
Monitoring Parameters
- HbA1c every 3 months initially, then every 6 months once stable (target < 7%)
- Fasting and postprandial blood glucose
- Renal function (eGFR) at least annually
- Vitamin B12 levels periodically (long-term metformin)
- Signs/symptoms of hypoglycemia
Rationale for This Triple Combination
The three drugs work at complementary sites with no overlapping mechanisms:
- Glimepiride fixes the insulin secretory defect
- Metformin reduces hepatic glucose overproduction and fasting hyperglycemia
- Voglibose specifically targets the postprandial glucose surge
A 2025 randomized Phase IV trial (PMID 41979234) comparing the triple FDC (glimepiride + voglibose + metformin-ER) against dual FDCs confirmed that the triple combination provides superior HbA1c reduction from baseline compared to dual-drug regimens in patients with T2DM poorly controlled on metformin alone.
Reading File
Finding Sources
Finding Sources
Searching the Web
Tribet 2 Abbott pioglitazone glimepiride metformin composition uses
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Correction - Tribet 2 Actual Composition
I apologize for the error in my previous answer. The image you shared clearly shows the correct composition:
Tribet 2 - Corrected Drug Profile
Composition (from the strip label)
Tribet 2 is manufactured by Abbott Healthcare Pvt. Ltd. and is a bilayered tablet containing:
| Component | Strength |
|---|---|
| Pioglitazone Hydrochloride IP | 15 mg (equivalent to Pioglitazone) |
| Glimepiride IP | 2 mg |
| Metformin Hydrochloride IP (extended-release) | 500 mg |
Note: The previous answer I gave was for a different combination (Glimepiride + Metformin + Voglibose), which goes by brand names like Trivolib, Glimitab MV, or Amaryl MV - not Tribet 2. Tribet 2 contains Pioglitazone, not Voglibose.
Indication
Type 2 Diabetes Mellitus (T2DM) - as third-line therapy in adults when diet, exercise, and dual oral antidiabetic therapy have failed to achieve adequate glycemic control.
Component Mechanisms
1. Glimepiride 2 mg - Sulfonylurea (Insulin Secretagogue)
Mechanism: Blocks ATP-sensitive K⁺ channels on pancreatic β-cells → membrane depolarization → Ca²⁺ influx → exocytosis of insulin. It is a second-generation sulfonylurea, taken once daily. The 2 mg dose is an intermediate dose (max 8 mg/day). - Lippincott Illustrated Reviews Pharmacology
- Targets: Impaired insulin secretion (the core β-cell defect in T2DM)
- Key risk: Hypoglycemia and weight gain
2. Pioglitazone 15 mg - Thiazolidinedione (TZD) / Insulin Sensitizer
Mechanism: Pioglitazone is a ligand for the PPARγ (peroxisome proliferator-activated receptor gamma) nuclear receptor, expressed primarily in adipose tissue. PPARγ activation promotes:
- Adipocyte differentiation and fatty acid uptake into fat cells
- Increased insulin-mediated glucose uptake in muscle and adipose tissue by 30-50%
- Reduced hepatic glucose production (HGP)
- Shift of triglyceride stores from visceral to subcutaneous fat depots
In net effect, pioglitazone reduces insulin resistance - the other major defect in T2DM. - Goodman & Gilman's Pharmacological Basis of Therapeutics
Pharmacokinetics:
- Dosed once daily; starting dose 15-30 mg, maximum 45 mg/day
- Onset of glucose-lowering is slow: maximal effect develops over 1-3 months
- Metabolized by the liver (CYP2C8, CYP3A4); can be used in renal insufficiency but NOT in active hepatic disease
- Pioglitazone also reduces triglycerides by 10-15% and raises HDL cholesterol
3. Metformin 500 mg ER (Extended-Release) - Biguanide
Mechanism: Primarily reduces hepatic gluconeogenesis (targets fasting hyperglycemia). Also improves peripheral insulin sensitivity and slows intestinal glucose absorption. Does NOT stimulate insulin secretion. - Lippincott Illustrated Reviews Pharmacology
- ER formulation reduces GI side effects and allows once-daily dosing
- Not protein-bound, not metabolized - excreted unchanged by kidneys
- Key safety concern: lactic acidosis (rare, mainly in renal failure)
Rationale for This Triple Combination
The three drugs address the three main pathophysiological defects of T2DM simultaneously:
| Defect | Drug |
|---|---|
| Impaired insulin secretion from β-cells | Glimepiride |
| Insulin resistance in muscle/adipose/liver | Pioglitazone |
| Hepatic overproduction of glucose | Metformin ER |
How to Take
- One tablet twice daily, before meals (as prescribed)
- Dose should be individualized; start low and titrate based on response
- Schedule H (Prescription-only) drug in India
Adverse Effects
| Component | Key Adverse Effects |
|---|---|
| Glimepiride | Hypoglycemia, weight gain |
| Pioglitazone | Fluid retention/edema, weight gain, risk of heart failure exacerbation, increased risk of bladder cancer (long-term use >1 year, controversial), elevated liver enzymes, bone fractures (especially in women) |
| Metformin ER | GI upset (reduced with ER form), lactic acidosis (rare), Vitamin B12 deficiency |
Key Contraindications
- Type 1 DM / DKA
- Heart failure (NYHA Class III-IV) - pioglitazone causes fluid retention
- Renal impairment (eGFR < 30) - metformin contraindicated
- Active hepatic disease / elevated liver enzymes (>2.5x ULN) - pioglitazone
- Bladder cancer (current or history) - pioglitazone
- Pregnancy and lactation
- Hypersensitivity to any component
Drug Interactions
- Glimepiride potentiated by: NSAIDs, salicylates, sulfonamides, fibrates, warfarin, MAO inhibitors
- Pioglitazone: Gemfibrozil (CYP2C8 inhibitor) can increase pioglitazone levels ~2-fold (dose reduction needed); Rifampin reduces levels significantly
- Metformin: cationic drugs (cimetidine, trimethoprim) increase metformin accumulation; hold before IV contrast
Monitoring
- HbA1c every 3 months (target < 7%)
- Fasting & postprandial blood glucose
- Liver function tests (LFTs) before starting pioglitazone and periodically
- Renal function (eGFR) at least annually
- Signs of fluid retention / heart failure
- Vitamin B12 levels periodically
This is a shared conversation. Sign in to Orris to start your own chat.